, making it available for use by U.S. federal agencies through the FedRAMP Marketplace.){kind=link}
A digital research platform developed by Vibrent Health has received Moderate Authority to Operate under the Federal Risk and Authorization Management Program (FedRAMP®), making it available for use by U.S. federal agencies through the FedRAMP Marketplace. This approval signals that the platform meets the U.S. government’s standards for security and privacy in cloud computing, including those outlined in NIST Special Publication 800-53 and the Health Insurance Portability and Accountability Act.
The platform, described as a Digital Health Research Cloud for Government, is designed to support health and clinical research conducted by federal agencies. It includes tools for participant recruitment, data collection, and integration of diverse health data types, such as electronic health records, claims, genomics, and wearable device outputs.
FedRAMP authorization is a prerequisite for federal agencies to adopt commercial cloud-based technologies involving sensitive federal data, including protected health information and personally identifiable information. Prior to this authorization, there were limited commercial off-the-shelf digital tools available that met these standards for health research.
This development could streamline procurement and reduce startup times for government-sponsored studies by eliminating redundant security assessments. Agencies such as the National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), Department of Veterans Affairs, Department of Defense, and others may benefit from faster deployment of digital infrastructure for large-scale or distributed research projects.
Vibrent’s platform is currently used in several major federally funded initiatives, including the NIH’s All of Us Research Program and various BARDA and National Cancer Institute programs. It supports a range of study models, including hybrid and decentralized designs, and offers functionalities such as participant engagement, longitudinal data collection, data integration, and regulatory compliance (including 21 CFR Part 11).
Praduman Jain, CEO of Vibrent Health, noted that the authorization reduces a key barrier to working with federal partners, particularly when handling sensitive health data. “Security and participant trust are non-negotiable in health research.”